120 related articles for article (PubMed ID: 9507701)
1. Synthesis and evaluation of 1,5-benzodiazepines with bridged cycloalkyl substituents at the N-1 position as potent and selective CCK-B Ligands.
Finizia G; Donati D; Pentassuglia G; Polinelli S; Tarzia G; Tranquillini ME; Ursini A
Arch Pharm (Weinheim); 1998 Jan; 331(1):41-4. PubMed ID: 9507701
[TBL] [Abstract][Full Text] [Related]
2. Synthesis and SAR of new 5-phenyl-3-ureido-1,5-benzodiazepines as cholecystokinin-B receptor antagonists.
Ursini A; Capelli AM; Carr RA; Cassarà P; Corsi M; Curcuruto O; Curotto G; Dal Cin M; Davalli S; Donati D; Feriani A; Finch H; Finizia G; Gaviraghi G; Marien M; Pentassuglia G; Polinelli S; Ratti E; Reggiani AM; Tarzia G; Tedesco G; Tranquillini ME; Trist DG; Van Amsterdam FT
J Med Chem; 2000 Oct; 43(20):3596-613. PubMed ID: 11020274
[TBL] [Abstract][Full Text] [Related]
3. Selective non-peptide ligands for an accommodating peptide receptor. Imidazobenzodiazepines as potent cholecystokinin type B receptor antagonists.
Bock MG; DiPardo RM; Newton RC; Bergman JM; Veber DF; Freedman SB; Smith AJ; Chapman KL; Patel S; Kemp JA
Bioorg Med Chem; 1994 Sep; 2(9):987-98. PubMed ID: 7712133
[TBL] [Abstract][Full Text] [Related]
4. Novel 1,5-benzodiazepines as CCK-B ligands. Effect of aryl-carbamic substituents at the C-3 position together with halogen substitution on the benzo-fused ring.
Tranquillini ME; Cassarà PG; Corsi M; Curotto G; Donati D; Finizia G; Pentassuglia G; Polinelli S; Tarzia G; Ursini A; van Amsterdam FT
Arch Pharm (Weinheim); 1997 Nov; 330(11):353-7. PubMed ID: 9431027
[No Abstract] [Full Text] [Related]
5. Diastereomeric separation of 1,5-benzodiazepines due to the presence of a chiral centre on the N-5 alkylic chain.
Araldi GL; Donati D; Tranquillini ME; Ursini A
Farmaco; 1998 Jan; 53(1):49-54. PubMed ID: 9543726
[TBL] [Abstract][Full Text] [Related]
6. Relationship between dihedral angles of N1 and C9 substituents in 1,4-benzodiazepines and dual cholecystokinin-A and -B antagonistic activities.
Tabuchi S; Nakanishi I; Satoh Y
Bioorg Med Chem Lett; 1998 Jun; 8(12):1449-54. PubMed ID: 9873368
[TBL] [Abstract][Full Text] [Related]
7. 5-(Piperidin-2-yl)- and 5-(homopiperidin-2-yl)-1,4-benzodiazepines: high-affinity, basic ligands for the cholecystokinin-B receptor.
Castro JL; Broughton HB; Russell MG; Rathbone D; Watt AP; Ball RG; Chapman KL; Patel S; Smith AJ; Marshall GR; Matassa VG
J Med Chem; 1997 Aug; 40(16):2491-501. PubMed ID: 9258356
[TBL] [Abstract][Full Text] [Related]
8. Potent and subtype-selective CCK-B/gastrin receptor antagonists: 2,4-dioxo-1,5-benzodiazepines with a plane of symmetry.
Hagishita S; Seno K; Kamata S; Haga N; Ishihara Y; Ishikawa M; Shimamura M
Bioorg Med Chem; 1997 Jul; 5(7):1433-46. PubMed ID: 9377103
[TBL] [Abstract][Full Text] [Related]
9. Development of 1,4-benzodiazepine cholecystokinin type B antagonists.
Bock MG; DiPardo RM; Evans BE; Rittle KE; Whitter WL; Garsky VM; Gilbert KF; Leighton JL; Carson KL; Mellin EC
J Med Chem; 1993 Dec; 36(26):4276-92. PubMed ID: 8277510
[TBL] [Abstract][Full Text] [Related]
10. Quantitative structure-activity relationship studies on 5-phenyl-3-ureido-1,5-benzodiazepine as cholecystokinin-A receptor antagonists.
Agrawal VK; Sharma R; Khadikar PV
Bioorg Med Chem; 2002 Nov; 10(11):3571-81. PubMed ID: 12213472
[TBL] [Abstract][Full Text] [Related]
11. 1,4-Benzodiazepine peripheral cholecystokinin (CCK-A) receptor agonists.
Sherrill RG; Berman JM; Birkemo L; Croom DK; Dezube M; Ervin GN; Grizzle MK; James MK; Johnson MF; Queen KL; Rimele TJ; Vanmiddlesworth F; Sugg EE
Bioorg Med Chem Lett; 2001 May; 11(9):1145-8. PubMed ID: 11354363
[TBL] [Abstract][Full Text] [Related]
12. Cholecystokinin-A receptor ligands based on the kappa-opioid agonist tifluadom.
Bock MG; DiPardo RM; Evans BE; Rittle KE; Whitter WL; Veber DF; Freidinger RM; Chang RS; Chen TB; Lotti VJ
J Med Chem; 1990 Jan; 33(1):450-5. PubMed ID: 2153212
[TBL] [Abstract][Full Text] [Related]
13. Cholecystokinin antagonists. Synthesis and biological evaluation of 4-substituted 4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepines.
Bock MG; DiPardo RM; Evans BE; Rittle KE; Veber DF; Freidinger RM; Chang RS; Lotti VJ
J Med Chem; 1988 Jan; 31(1):176-81. PubMed ID: 3336017
[TBL] [Abstract][Full Text] [Related]
14. Quantitative structure-activity relationship study on some nonpeptidal cholecystokinin antagonists.
Sinha J; Kurup A; Paleti A; Gupta SP
Bioorg Med Chem; 1999 Jun; 7(6):1127-30. PubMed ID: 10428383
[TBL] [Abstract][Full Text] [Related]
15. Combinatorial solid phase synthesis of multiply substituted 1,4-benzodiazepines and affinity studies on the CCK2 receptor (part 1).
Lattmann E; Billington DC; Poyner DR; Arayarat P; Howitt SB; Lawrence S; Offel M
Drug Des Discov; 2002; 18(1):9-21. PubMed ID: 12375632
[TBL] [Abstract][Full Text] [Related]
16. Recent advances in the chemistry of cholecystokinin receptor ligands (agonists and antagonists).
de Tullio P; Delarge J; Pirotte B
Curr Med Chem; 1999 Jun; 6(6):433-55. PubMed ID: 10213792
[TBL] [Abstract][Full Text] [Related]
17. Synthesis, biological evaluation, and quantitative receptor docking simulations of 2-[(acylamino)ethyl]-1,4-benzodiazepines as novel tifluadom-like ligands with high affinity and selectivity for kappa-opioid receptors.
Cappelli A; Anzini M; Vomero S; Menziani MC; De Benedetti PG; Sbacchi M; Clarke GD; Mennuni L
J Med Chem; 1996 Feb; 39(4):860-72. PubMed ID: 8632410
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and evaluation of N1-substituted-3-propyl-1,4-benzodiazepine-2-ones as cholecystokinin (CCK2) receptor ligands.
Lattmann E; Sattayasai J; Billington DC; Poyner DR; Puapairoj P; Tiamkao S; Airarat W; Singh H; Offel M
J Pharm Pharmacol; 2002 Jun; 54(6):827-34. PubMed ID: 12078999
[TBL] [Abstract][Full Text] [Related]
19. Design of nonpeptidal ligands for a peptide receptor: cholecystokinin antagonists.
Evans BE; Rittle KE; Bock MG; DiPardo RM; Freidinger RM; Whitter WL; Gould NP; Lundell GF; Homnick CF; Veber DF
J Med Chem; 1987 Jul; 30(7):1229-39. PubMed ID: 2885419
[TBL] [Abstract][Full Text] [Related]
20. Pharmacological profile of (R)-1-[2,3-dihydro-1-(2'-methylphenacyl)-2-oxo- 5-phenyl-1H-1,4-benzodiazepin-3-yl]-3-(3-methylphenyl)urea (YM022), a new potent and selective gastrin/cholecystokinin-B receptor antagonist, in vitro and in vivo.
Nishida A; Miyata K; Tsutsumi R; Yuki H; Akuzawa S; Kobayashi A; Kamato T; Ito H; Yamano M; Katuyama Y
J Pharmacol Exp Ther; 1994 May; 269(2):725-31. PubMed ID: 7910212
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
